Department of Medicinal Chemistry, Medical University of Lublin, Staszica 4, PL 20-081 Lublin, Poland.
Pharmacol Rep. 2009 Sep-Oct;61(5):885-91. doi: 10.1016/s1734-1140(09)70145-8.
The aim of this work was to evaluate the possibility of using of the new selenoorganic ring compound, 3-(o-chlorobenzoylamino)-2-(o-tolylimino)-4-methyl-4-selenazoline, as a selenium supplement by investigating the influence of its short-term administration on Se accumulation and antioxidant status in kidney. For 10 days, adolescent male Wistar rats were treated with saline (control group), Na(2)SeO(3) (Se-IN group) or the studied compound (Se-ORG group) (5 x 10(-4) mg Se/g of once a day) via a stomach tube. The selenium concentration, total antioxidant status (TAS), activities of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), concentrations of ascorbic acid (AA) and reduced glutathione (GSH) and concentration of malonyldialdehyde (MDA) were determined in the kidney homogenates. TAS was significantly reduced in the Se-ORG group compared to the control. Reduced glutathione was markedly decreased in Se-treated animals compared to the control and in the Se-ORG group compared to the Se-IN group. Malonyldialdehyde was significantly increased in the Se-supplemented groups compared to the control group but considerably less so in the Se-ORG group. All other studied parameters displayed no significant differences. No increase in the accumulation of selenium and the partial impairment of the antioxidant status and enhancement of lipid peroxidation in the kidneys resulting from Se treatment could suggest that in the first period of administration, excess selenium was excreted with urine, leading to a disturbance of kidney functions. Comparison of the effect of our compound with that exerted by inorganic Na(2)SeO(3) suggests that the studied compound could be considered as a possible supplement after further investigations, including determination of selenium excretion with urine, as well as repetition of this study using a wide range of doses and periods of supplementation.
本研究旨在评估新型有机硒环化合物 3-(邻氯苯甲酰氨基)-2-(邻甲苯亚氨基)-4-甲基-4-硒唑啉作为硒补充剂的可能性,通过研究其短期给药对肾脏硒积累和抗氧化状态的影响来评估。在 10 天的时间里,通过胃管向青春期雄性 Wistar 大鼠给予生理盐水(对照组)、亚硒酸钠(Se-IN 组)或研究化合物(Se-ORG 组)(每天 5 x 10(-4) mg Se/g,一次)。在肾匀浆中测定硒浓度、总抗氧化状态(TAS)、抗氧化酶超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)的活性、抗坏血酸(AA)和还原型谷胱甘肽(GSH)的浓度以及丙二醛(MDA)的浓度。与对照组相比,Se-ORG 组的 TAS 显著降低。与对照组相比,硒处理动物的还原型谷胱甘肽明显减少,与 Se-ORG 组相比,与 Se-IN 组相比,丙二醛显著增加。与对照组相比,所有补充硒的组的 MDA 均显著增加,但 Se-ORG 组的增加幅度较小。其他研究参数没有显示出显著差异。由于硒处理导致肾脏硒积累增加、抗氧化状态部分受损和脂质过氧化增强,这表明在给药的第一个时期,过量的硒随尿液排出,导致肾脏功能紊乱。与无机 Na(2)SeO(3) 相比,我们的化合物的效果表明,在进一步研究后,该化合物可以被认为是一种可能的补充剂,包括通过尿液测定硒排泄,以及使用更广泛的剂量和补充期重复这项研究。